BridgeBio Oncology Therapeutics, Inc. - 8-K Filing

BridgeBio Oncology Therapeutics reports Q3 2026 net loss of $34.2 million and clinical updates for BBO-8520. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 10, 2026, 21:18 UTC

Tickers: $BBOT

Read the full article at SEC EDGAR

More Regulatory news

WOLVERINE WORLD WIDE INC /DE/ - 10-Q Filing SEC EDGAR · November 12, 2026, 16:24 UTC
BlueOne Technologies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:20 UTC
Newton Golf Company, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 16:14 UTC
XBiotech Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:53 UTC
Cohen & Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:48 UTC
UNITED BANCORP INC /OH/ - 10-Q Filing SEC EDGAR · November 12, 2026, 15:33 UTC
PATRIOT GOLD CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 15:32 UTC
First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC